Efficient Portfolio Selection

Merak believed that an efficient frontier analysis method that combined the robustness of the Monte Carlo approach with the confidence of the Markowitz approach would be a very powerful tool for any industry. However, it soon became clear that there are other ways to address the problem that do not require a Monte Carlo component. Three subgroups were formed, and each developed a different approach for solving the problem. These were the Portfolio Selection Algorithm Approach, the Statistical Inference Approach, and the Integer Programming Approach

Based on results obtained at the Seventh Annual PIMS Industrial Problem Solving Workshop

Introduction The behaviour of consumers is believed to be influenced by many factors. Some of these factors include the individuals culture, social status, lifestyle and attitudes. Understanding how these complicated and interrelated factors drive the consumer is the primary goal of Manifold Data Mining. The question posed to the group was to 1) find an algorithm that predicts the likelihood of consumers to respond favourably to a given product. In addition, once this prediction is made for a given consumer the group was also asked to 2) develop a second algorithm that infers other statistical information regarding the consumer. Manifold Data Mining has developed innovative demographic and household spending pattern databases for six-digit postal codes in Canada. Their collection of information consists of both demographic and expenditure variables which are expressed through thousands of individually tracked factors. This large collection of information about consumer behaviour is typically referred to as a mine. Although very large in practice, for the purposes of this report, the data mine consisted of m individuals and n factors where m 2000 and n 50. Ideally, the first algorithm would identify a few factors in the data mine which would differentiate customers in terms of a particular product preference. Then the second algorithm would build on this information by looking for patterns in the data mine which would identify related areas of consumer spending. To test the algorithms two case studies were undertaken. The first study involved differentiating BMW and Honda car owners. The algorithms developed were reasonably successful at both finding questions that differentiate these two populations and identifying common characteristics amongst th

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Recurrence relations for single and product moments of progressive Type-II right censored order statistics from exponential and truncated exponential distributions

Progressive Type-II right censored order statistics, single moments, product moments, recurrence relations, exponential distribution, right truncated exponential distribution,

Relationships for moments of order statistics from the right-truncated generalized half logistic distribution

Order statistics, recurrence relations, single moments, product moments, generalized half logistic distribution, right-truncated distribution, IFR family,

PRODUCT-DRIVEN DATA MINING

1 Introduction The behaviour of consumers is believed to be influenced by many factors. Some of these factors include the individuals culture, social status, lifestyle and attitudes. Understanding how these complicated and interrelated factors drive the consumer is the primary goal of Manifold Data Mining. The question posed to the group was to 1) find an algorithm that predict

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

IMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes